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ARTI CLE I NFO

ABSTRACT

Article history:

Research on acetaminophen (APAP) toxicity over the last several decades has focused on the pathophysiology of
liver injury, but increasingly attention is paid to other known and possible adverse effects. It has been known for
decades that APAP causes acute kidney injury, but confusion exists regarding prevalence, and the mechanisms have
not been well investigated. More recently, evidence for pulmonary, endocrine, neurological, and neurodevelopmental
toxicity has been reported in a number of published experimental, clinical, and epidemiological studies, but the
quality of those studies has varied. It is important to view those data critically due to implications for regulation and
clinical practice. Here, we review evidence and proposed mechanisms for extrahepatic adverse effects of APAP and
weigh weaknesses and strengths in the available data.
Relevance for patients: APAP is one of the most commonly used drugs in the West. Although it is generally
considered safe when used according to manufacturer recommendations, it has been known for decades that overdose
can cause liver injury. Recent studies have suggested that APAP can damage cells in other organs as well, leading to
calls for more and stricter regulations, which would limit use of this otherwise effective drug. It is especially
important to view claims of developmental effects of antenatal APAP exposure with a critical eye because APAP is
currently the only over-the-counter medication recommended for pregnant women to self-treat pain and fever.
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1. Introduction
Acetaminophen (APAP; a.k.a. paracetamol) is one of the
most commonly used drugs in the US [1] and throughout the
West, but has a relatively low therapeutic index. The major
target organ of APAP toxicity is the liver. In fact, APAP is the
principal cause of acute liver failure (ALF) and related deaths
in several countries [2]. The hepatotoxicity of APAP was first
reported in the 1960s [3-5]. In the five decades since those initial
reports, studies of APAP toxicity have focused almost exclusively
on the prevalence and mechanisms of liver injury. Recently,
however, attention has shifted toward other adverse effects. A
large number of studies have reported neurological [6-14],
pulmonary [15-21] and developmental toxicity [6,7,11,14,22]
in both preclinical models and humans.

It is important to critically evaluate the evidence for toxic
effects of any drug or other xenobiotic. Claims of toxicity can
lead to changes in clinical practice or regulation that can affect
patient care. Recently, concerns regarding liver injury caused by
APAP have led the US FDA to reduce the maximum amount of
APAP allowed in prescription formulations to 325 mg, and to
recommend lower daily doses for over-the-counter use [23]. It
is especially important to view claims of developmental and
congenital effects of intrauterine APAP exposure with a critical
eye because APAP is currently the most commonly used drug
among pregnant women and for many years was the only
analgesic considered safe for use during pregnancy [24,25], a
perception that still exists among many clinicians and patients.
An association between APAP use in pregnancy and disease in
offspring could easily lead to changes in clinical practice,
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just as associations between NSAIDs and various adverse
outcomes such as low birth weight, birth defects, and child
mortality led the FDA to classify aspirin and others as
category D for pregnancy, meaning that there is positive
evidence for maternal fetal risk, and caused clinicians to
recommend against their use [24].
The purpose of this review is to summarize studies of
adverse extrahepatic effects of APAP and to evaluate the
evidence for those effects. Animal studies, human studies and
epidemiological reports are discussed. Special attention is
given to the pathophysiological mechanisms that have been

proposed to explain the phenotypic findings from those data.
The review begins with what is known about the mechanisms
of toxicity in the liver, and findings from other organs are
discussed with reference to those well-known mechanisms.
Overall, it is clear that APAP is toxic in other organs, but the
quality of the evidence and mechanisms varies. In many cases,
there is a paucity of mechanistic data, or the available
mechanistic studies suffer from poor design. However, that
does not necessarily invalidate observations of adverse effects. We
strongly recommend that future investigations use only reliable
in vivo models and doses that are relevant for the human
context.

Table 1. Proposed extra-hepatic adverse effects of APAP
Toxicity

Evidence

Proposed mechanisms

Comments

Renal

Clinical and rodent studies

Protein binding, ɤ-glutamyl cycling

Strong human and rodent data

Pulmonary

Epidemiology, limited preclinical studies

GSH depletion, oxidative stress, neurogenic inflammation

Better study designs needed

Endocrine

Epidemiology, limited preclinical studies

Altered sex steroid metabolism, inhibition of prostaglandin Conflicting human and experimental
synthesis
data

Ototoxicity

Case reports, limited preclinical studies

Oxidative stress, ER stress

Neurobehavioral

Epidemiology, limited preclinical studies

Endocrine disruption, endocannabinoid signaling, direct
Better study designs needed
neurotoxicity

2. Overview of APAP metabolism and hepatotoxicity
Although several critical details are still missing, the
metabolism and toxicity of APAP in the liver have been
thoroughly investigated [26] ( Figure 1). After therapeutic doses,
approximately one-third is glucuronidated while another third
is sulfated [26, 27 ]. Any remaining parent compound is
converted by cytochrome P450 enzymes to an electrophilic
intermediate, believed to be N-acetyl-p-benzoquinone imine
(NAPQI) [28]. Binding of the reactive metabolite to proteins
is known to be the initiating event in liver injury [29-32].
Binding to mitochondrial proteins appears to be particularly
important. Changes in mitochondrial function and integrity
are known to occur in the liver after APAP overdose in both
mice and humans [15, 33 - 36 ]. Interestingly, the reactive
metabolite of N-acetyl-p-aminophenol (AMAP), an isomer of
APAP, binds much less to mitochondrial proteins in primary
mouse hepatocytes (PMH) than the metabolite of APAP, and
PMH are much less susceptible to the toxicity of AMAP than
of APAP [37]. Furthermore, unlike PMH, AMAP treatment
does result in mitochondrial protein adducts in primary
human hepatocytes (PHH) [37], which are damaged by AMAP
[37,38]. Finally, rats are less susceptible to APAP hepatotoxicity
than mice and also have less mitochondrial protein binding after
APAP overdose [39]. Together, those data strongly suggest that
mitochondrial protein binding is critical.
Although it is not known exactly how it occurs, the
mitochondrial protein binding seems to cause oxidative stress.
The major reactive oxygen species (ROS) in APAP hepatotoxicity
are superoxide (O2-) and peroxynitrite (ONOO-) [40], which form
primarily within mitochondria and drive the injury [40-46].
Distributed under creative commons license 4.0

Strong human data,
experimental data

conflicting

Replenishment of glutathione by treatment with the precursor
N-acetylcysteine (NAC) protects against APAP hepatotoxicity
not only by scavenging the reactive metabolite of APAP, but also
by reducing oxidative stress [47,48].
The initial oxidative stress after APAP overdose activates
mitogen - activated protein kinases (MAPKs), including the cJun N-terminal kinases (Jnk) 1/2 [49,50] ( Figure 1). The role of
Jnk 1/2 is controversial. The Jnk 1/2 inhibitor SP600125 protects
against APAP toxicity in mice in vivo and in both PMH and
PHH [51,52]. Although some groups have also shown
protection with knockdown or knockout of Jnk isoforms,
particularly Jnk2 [51], others have failed to reproduce those
results [52-55]. The discrepancy between different studies that
utilized Jnk2 deficient mice may be due to use of control
animals from different substrains [56]. Interestingly, one recent
study demonstrated that neither Jnk 1 nor combined Jnk 1/2
deficiency in the liver is protective against APAP hepatotoxicity
[55]. In fact, Jnk1/2 knockout appeared to worsen injury [55].
Furthermore, SP600125 protected in the double knockout mice
[55]. The authors concluded that Jnk 1/2 is not part of the
mechanism of toxicity and that SP600125 protects through offtarget effects [55]. However, those results do not explain why
other Jnk 1/2 inhibitors also protect against APAP [53,57].
Overall, the weight of the evidence favors a role for Jnk [58].
Once activated, Jnk 1/2 translocates to mitochondria [44,59], and it
is thought that it enhances the mitochondrial oxidative stress
[59,60]. Other kinases that have been shown to play a role in
mice include the mixed lineage kinase 3 (Mlk3) [61] and the
receptor interacting protein kinases (Ripk) 1 and 3 [62-64];
however, their exact mechanisms are unclear.
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Figure 1. Pathophysiology of APAP-induced liver and kidney injury.
Most of a dose of acetaminophen (APAP) is glucuronidated or sulfated
in the liver and then excreted. A small percentage in both the liver and kidney
is converted to the electrophilic intermediate N-acetyl-p-benzoquinone
imine (NAPQI). NAPQI can be detoxified by reaction with glutathione
(GSH), which depletes GSH stores. NAPQI can also bind to proteins,
which leads to cell death. The mechanisms of cell death in the liver
include mitochondrial oxidative stress, c-Jun N-terminal kinase (JNK)
activation and nuclear DNA fragmentation (inset). In the kidney, GSH
depletion is exacerbated by the GGT cycle, which enhances the
nephrotoxicity.

The mitochondrial permeability transition (MPT) is also a
critical step in the mechanism of APAP-induced liver injury
( Figure 1). MPT inhibitors and genetic deletion of MPT pore
components protect against APAP hepatotoxicity both in vitro
and in vivo [34,65-67]. The resulting mitochondrial swelling
leads to lysis of mitochondria and release of mitochondrial
contents [35,68,69]. Mitochondrial endonucleases, in particular,
are liberated and translocate to nuclei where they cleave
genomic DNA [69]. Although nuclear DNA fragmentation is
widely considered a hallmark of apoptosis, oncotic necrosis is
actually the major mode of cell death in the liver after APAP
overdose. Studies in both humans and mice demonstrate that
apoptosis has, at most, a minor role [70-73].
In addition to the intracellular mechanisms of toxicity described
above, results from numerous studies have demonstrated that
inflammation may enhance APAP-induced liver injury
[74,75]. The earliest evidence for a contribution of inflamemation to APAP hepatotoxicity was the finding that resident
macrophages in the liver (Kupffer cells) are activated after
APAP overdose in rats [76] and that inhibition of macrophages with gadolinium chloride was protective in that model
[ 77 ]. The latter finding was later repeated in mice [ 78 ].
Similarly, it was also reported that antibodies against
neutrophils can protect against APAP hepatotoxicity in rats and
mice [79,80]. Finally, damage-associated molecular patterns
(DAMPs) are released during APAP hepatotoxicity in both
mice and humans [35,36] and several studies revealed that
inhibition of Nalp3 inflammasome-mediated DAMP signaling
in myeloid cells can reduce the injury [81-84]. However, the
conclusions from those studies are controversial. Gadolinium
chloride has numerous effects other than macrophage inactivation
that could also explain protection against hepatotoxicity, and it
was reported that targeting macrophages with liposomal
Distributed under creative commons license 4.0
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clodrinate actually exacerbated the APAP-induced liver injury
[85]. Furthermore, deficiency of Nalp3 signaling components
does not protect against APAP toxicity, and modulation of IL-1β
signaling also has no effect [86,87]. For more detailed information
about sterile inflammation in APAP hepatotoxicity, the reader is
directed to two excellent reviews that have recently been
published [74,75].
Importantly, it appears that the mechanisms of APAP
hepatotoxicity are the same in both humans and mice. Both
GSH depletion [88,89] and APAP-protein binding are known
to occur in humans [27,90] and oxidative stress, Jnk 1/2 activation
and the MPT have been demonstrated in human hepatocytes
treated with APAP [50,73]. Finally, there is evidence that
mitochondrial damage is important in human APAP
hepatotoxicity too [35,36,91].

3. Nephrotoxicity
Evidence. Numerous studies have shown that large doses of
APAP can cause kidney injury in rodent models [4,15,92-96] and
many reports of kidney injury in humans after APAP overdose
have been published [3,97-102]. An often-cited figure for the
overall incidence of renal dysfunction in patients diagnosed with
APAP overdose is approximately 1%. However, this was
derived from a single early review of unselected patients
diagnosed with “APAP poisoning” at a single center in the UK
[103]. Multiple reports suggest that the prevalence of renal injury
among APAP overdose patients who develop liver injury is
much greater; values from 10% to 79% have been reported
[98,99,102-105]. One study found that circulating creatinine
levels were ≥ 2 mg/dL (177 µmol/l) (reference interval: 0.7-1.2
mg/dL or 60–115 µmol/l) in approximately 50% of APAPinduced ALF patients, and the levels were higher in nonsurvivors compared to survivors [105]. Those data were
supported by later studies that showed plasma creatinine level
at admission and serum kidney injury molecule 1 (KIM-1) are
predictive of poor patient outcome after APAP overdose
[98,106]. Interestingly, some evidence suggests that chronic use
of low doses of APAP can increase risk for kidney disease and
cause analgesic nephropathy [107,108], although that has been
questioned by findings from very large studies of “healthy”
individuals who regularly use over-the-counter analgesics including
APAP [108].
Proposed mechanisms. Although the nephrotoxicity of APAP
has been known about for decades, surprisingly few studies
have explored the mechanisms. Early on, it was thought that
endotoxemia as a result of failure of the damaged liver to
eliminate endotoxins from the normal GI flora was responsible
for the renal damage [104], but results from later studies suggested
a more direct effect involving reactive metabolites of APAP
and APAP-protein binding [109]. There are significant species
differences, and even within-species strain differences, in renal
metabolism of APAP [110]. In Fischer F344 rats, APAP and
NAPQI appear to be converted to p-aminophenol (PAP) by
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deacetylation in the kidney, and PAP can be further metabolized
to a reactive quinone imine other than NAPQI, possibly by a
prostaglandin endoperoxide synthase (PGES; aka cyclooxygenase, COX) [110-115]. Based on those data, it was initially
thought that APAP nephrotoxicity was mediated by PAP.
However, it was later demonstrated that inhibition of
deacetylation had no effect on covalent protein binding in
renal microsomes from Sprague-Dawley (SD) rats [116], and
an antibody against the N-acetyl moiety of APAP-cysteine
could bind to APAP-protein adducts in the kidneys of mice after
APAP treatment but not after treatment with p-aminophenol
[ 117 ]. Furthermore, covalent binding in renal microsomes
from SD rats can be prevented by the P450 inhibitor 1aminobenzotriazole [116], and the nephrotoxicity of APAP in
mice is reduced by the P450 inhibitor piperonylbutoxide
[117]. It is also apparent that sex differences in APAP
nephrotoxicity in mice are due to differences in renal P450s.
Female mice are resistant to renal injury even at doses of
APAP that cause hepatotoxicity, and that is likely due to
hormone-induced differences in P450 expression. Castration
of male mice reduces APAP metabolism and protects against
APAP-induced kidney injury [ 118 ], while testosterone injections induce Cyp2e1 and render female mice susceptible to
APAP nephrotoxicity [ 119 ]. Together, those data strongly
suggest that APAP nephrotoxicity in mice is mediated at least in
part by P450s and the same reactive metabolite of APAP that
causes liver injury. Which species (mouse or rat) and which
strain (F344 or SD rats) is more relevant for human APAP
nephrotoxicity is not yet known. PAP and PAP metabolites have
been detected in urine from humans after APAP ingestion
[120,121], which may suggest that deacetylation of APAP to
PAP occurs in humans. However, PAP and APAP metabolism
are difficult to disentangle. Furthermore, we know that the
mouse is a better model for the liver injury caused by APAP
[39]. Aside from cytochrome P450s, results from studies
using isolated rabbit and human kidney microsomes have
indicated that a PGES/COX can also convert APAP to
NAPQI (via a phenoxy radical intermediate) [ 122 ]. Interestingly, more recent studies showed that renal injury after
APAP overdose in mice is exacerbated by free APAP-cysteine
from APAP-GSH [95,96]. APAP-cysteine generated from the
breakdown of APAP-GSH in the GI tract and kidneys can act
as an acceptor of the γ-glutamyl moiety of GSH in the GSH
cycle, and thereby exacerbate GSH depletion in the kidneys
[96].
Overall, it appears that NAPQI formation and protein
binding are critical, similar to the liver. There is also some
evidence that APAP can inhibit mitochondrial respiration in
kidney cells from rodents [123,124]. However, little is currently
known about APAP nephrotoxicity beyond those results.
Although it is tempting to assume that the mechanisms are the
same as in the liver due to the involvement of protein binding
and mitochondria, there is currently no direct evidence for
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oxidative stress, kinase activation, or the MPT in APAP
nephrotoxicity.
Biological relevance of proposed mechanisms. Nephrotoxicity
is clearly a risk after APAP overdose. Available data suggest
that protein binding and mitochondrial dysfunction occur in the
liver after APAP overdose and that the injury is exacerbated by
glutathione cycling, but much more work is needed to prove
the importance of those phenomena in APAP nephrotoxicity.
This is especially important because acute kidney injury is a
predictor of poor patient outcome after APAP overdose
[99,106], possibly because it contributes to death after APAP
overdose through multi-organ failure. The high affinity of the
PGES for APAP has prompted some to speculate that it is
responsible for the increased risk of kidney disease after chronic
low-dose exposure to the drug [122,110,115], but again, the
occurrence of APAP nephrotoxicity among therapeutic users is
controversial. We recommend that future research on APAP
nephrotoxicity be focused on the importance of mitochondrial
dysfunction and kinase signaling and treatments that could address
those, as well as mechanisms of renal cell recovery that have been
demonstrated to be important in other models of acute kidney
injury [125].

4. Pulmonary toxicity
Evidence. There is evidence for a link between chronic
APAP exposure at therapeutic doses and respiratory disease. A
survey of general practice clinic patients in the UK found a
positive association between frequency of APAP use and signs
of asthma [20]. The same group also found that regional sales
of acetaminophen in Europe correlated with incidence of
respiratory illnesses [126] and that prenatal exposure to APAP
may be associated with asthma, wheezing and other respiratory
problems later in life [127]. Since then, other groups have
obtained similar findings [128-130]. APAP exposure has also
been associated with development of chronic obstructive
pulmonary disease [131]. However, the conclusions from these
studies are controversial. Several possible confounding factors
have been suggested [132-134]. Among these, indication bias
(“reverse causation”) is probably of greatest concern. For
example, children with respiratory infections are more likely to
be exposed to APAP as a part of normal treatment [135], which
may lead to a false association between APAP exposure early
in life and later asthma when in fact the later respiratory
problems may be a result of the infection or related issues. There
is some evidence of pulmonary toxicity in rodent models.
Bronchiolar epithelium necrosis has been observed in mice
treated with very large doses of APAP [15,16,136], but those data
are clearly not relevant for the chronic low-dose exposures that
are thought by some to cause asthma and other lung diseases.
There is some evidence that low doses of APAP are
proinflammatory in the lungs [17]. Furthermore, adult mice that
were exposed to APAP in utero were found to have a greater
response to an allergic challenge later in life [18]. However,
DOI: http://dx.doi.org/10.18053/jctres.03.201703.005
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additional work
is needed to understand
the
pathophysiological significance of the latter phenomena.
Overall, there is currently a tentative link between APAP and
pulmonary disease that requires further investigation.
Proposed mechanisms. It has been suggested that chronic
exposure to APAP can deplete GSH in the lungs and that this
could explain a connection between APAP and respiratory
diseases if it enhances susceptibility to oxidants, such as reactiveoxygen species produced by inflammatory cells or even
environmental oxidants [20]. GSH depletion and increased
expression of oxidative stress response genes have been
detected in lungs from mice treated with large, acutely toxic
doses of APAP and that could suggest oxidative stress [137139 ]. APAP-protein binding in the lung has also been
demonstrated in mice [137,140-142]. In fact, one study found
that a polymorphism in glutathione-s-transferase (GST) P1
that reduces its activity was associated with wheeze in
children exposed to APAP prenatally [129], although a
conflicting study reported that wheezing and asthma in
children of mothers who used APAP during pregnancy is greater
when the mother possesses multiple copies of GSTP1 and/or
GSTM1 compared with null genotypes [139].
A more specific mechanism of APAP-induced lung disease
that has been proposed is neurogenic inflammation. Nassini et
al. [17] suggested that inflammation develops in the lungs
after APAP treatment due to activation of the transient
receptor potential ankyrin 1 (TRPA1) channel in peptidergic
neurons by NAPQI. They demonstrated that direct treatment
with NAPQI can enhance Ca2+ uptake in cells expressing
TRPA1. Importantly, there was also evidence for increased
TRPA1 signaling and evidence of inflammation in lungs from
rodents treated intratracheally with NAPQI or either intragastrically or intraperitoneally with relatively low doses of
APAP (15-300 mg/kg). The authors were even able to detect
sulfhydryl adducts after the 15 mg/kg dose, though it’s not
clear what effect this had on total GSH levels or if protein
binding actually occurred.
Biological relevance and future studies. Although GSH
depletion has been demonstrated in lungs from mice overdosed
with APAP, it is not clear if that occurs after repeated exposure
to APAP at therapeutic doses, which would be more relevant
for the reported epidemiological connections between APAP and
chronic lung disease. Moreover, the GSH depletion that has been
observed in lung is unimpressive: only about 30% of total
lung GSH is lost even after treatment with a dose as large as
500 mg/kg [137]. It is possible that the GSH depletion
selectively occurs in certain cell types in the lungs (e.g. Clara
cells), in which case the total GSH would not be expected to
dramatically change; however, covalent protein binding also
has not been observed except at very high doses [137,140142]. The TRPA1 hypothesis has more data to support its
biological relevance. Unfortunately, the authors of that study
used multiple models, including cultured cells, rat liver slices,
isolated guinea pig trachea and mice to perform different
Distributed under creative commons license 4.0
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experiments in the same study [17], and it’s not clear how each
model is related. Furthermore, there was no assessment of
pulmonary function in an in vivo model treated with APAP, so
the physiological consequences of the inflammation are
unknown. The authors did, however, test the effect of APAP on
pulmonary insufflation pressure in vivo in guinea pigs and
reported no change [17]. Thus, the evidence for TRPA1-mediated
lung damage in animals is preliminary and should be further
explored. Overall, it is not yet clear if or how APAP causes lung
disease. We recommend that experiments measuring GSH and
protein binding in the lungs be repeated in mice using low,
therapeutic doses to determine if those mechanisms are actually
relevant for humans. Presently, the most compelling data suggest
that NAPQI can activate TRPA1 on neurons and lead to
neurogenic airway inflammation, but a more detailed study
using only the mouse model, and that includes assessment of
pulmonary function, is needed to test that.

5. Endocrine disruption and sexual development
Evidence. It is critical to evaluate claims regarding longterm effects of intrauterine APAP exposure because APAP is
currently the only drug recommended for pregnant women to
reduce pain and fever. Modestly increased risk of cryptorchidism
after prenatal exposure to APAP has been reported in humans
in a few studies [143-145], which suggests some estrogenic or
anti-androgen activity of APAP. However, the results are
inconsistent and difficult to interpret together. For example, one
study examined two patient cohorts and discovered an effect in
only one of them [145]. Another study found that the risk of
cryptorchidism was increased in offspring of mothers who used
APAP for ≥ 4 weeks during pregnancy, but the likelihood of the
child undergoing orchiopexy (surgical treatment, and therefore a
surrogate marker of long-term cryptorchidism) was not [144].
Another study failed to find an association between APAP
alone and other measures of androgen exposure, such as penis
width and anogenital distance (AGD), commonly associated
with reproductive disorders, despite an association with APAP
and NSAIDs together [146]. Overall, there does not seem to be
a clear relationship between APAP exposure during
development and reproductive effects in humans. Nevertheless,
several studies using rodent models have indicated a connection.
One group has reported that intrauterine APAP exposure modestly
affects AGD in male and female rodents [145,147,148] and
may affect germ cell proliferation in female mice [148].
However, although they claimed to use subtoxic doses, the
authors treated the animals with 50-350 mg/kg of APAP every
morning for 7 days. While the maximum recommended dose of
APAP in humans is approximately 50-60 mg/kg/day, that
amount is typically divided into multiple smaller doses over a 24
h period. In fact, it is well known that a single treatment with
≥150 mg/kg is hepatotoxic in mice, resulting in significantly
elevated plasma ALT values and evidence of hepatocyte
DOI: http://dx.doi.org/10.18053/jctres.03.201703.005
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necrosis by histology [149]. It is not surprising that there may be
developmental abnormalities in offspring of animals that
suffer liver injury during pregnancy. In fact, the most surprising
finding from these studies may be that the effects were not
more pronounced. Adding confusion to the debate, the same
group recently found that 50 mg/kg/day has no effect on
masculine behaviors or morphology in a region of the brain
associated with those behaviors in male offspring [150], though
the 150 mg/kg/day dose did have an effect. Overall, there is
currently no clear association between APAP and
reproductive effects in offspring.
Proposed mechanisms. APAP does not seem to be directly
estrogenic [151], so other mechanisms have been proposed.
One possible mechanism for the suggested endocrine-disrupting
effects of APAP is altered sex steroid metabolism. Interestingly,
one research group obtained moderately elevated values for
total estrogen metabolites in urine from premenopausal
women who reported high APAP use [152]. The only rodent
in vivo study to address this issue revealed that plasma
testosterone decreased after APAP treatment in castrated mice
with human testis xenografts, which suggests that APAP
decreases testosterone production in human testes [153]. Finally,
a few in vitro studies have demonstrated that cytochrome
P450-mediated steroid metabolism can be altered by APAP
[154,155], though other studies have provided partially
conflicting results [ 156 ]. Treatment of an adrenocortical
carcinoma cell line resulted in increased pregnenolone and
decreased androstenedione and testosterone in two studies
[144,157]. Estrone and β-estradiol were also increased by APAP
[147]. However, another study found no effect of APAP on
testosterone production in human fetal testis [156]. Another
mechanism that has been proposed for the possible endocrinedisrupting effects of APAP is reduced prostaglandin synthesis
due to cyclooxygenase inhibition. Certain prostaglandin levels
have been shown to decrease in cultured human fetal testis after
APAP treatment [156].
Biological relevance and future studies. Altogether, there
are limited and conflicting results regarding the endocrine
effects of APAP. There is some epidemiological evidence for
modestly increased risk of indirect markers of abnormal sexual
development after intrauterine exposure to APAP in humans,
but those data are by no means conclusive. Although one human
study reported increased urine estrogen in humans after APAP
use [152], it is unlikely that the modest effect that was observed
would have a major impact on development. Even the
evidence for developmental effects of prenatal use of potent,
direct estrogens like oral contraceptives on sexual
development in offspring is weak at best [157]. While results
from some studies using cell culture models do support an
effect of APAP on hormone metabolism, others have revealed
conflicting results. Moreover, most of those studies involved
prolonged treatment (24-72 h) with µM to mM concentrations
of APAP, which is not consistent with the pharmacokinetics
Distributed under creative commons license 4.0

of APAP in vivo. Finally, the data from the human testis
xenograft model are compelling, but the human relevance of
that model is unclear. Overall, there is currently no strong
evidence that intrauterine exposure to APAP can significantly
alter sexual development or reproductive health later in life.
Before any further research on the endocrine and reproductive
effects of APAP or the mechanisms involved, we recommend
that a simple study be performed in which pregnant mice
receive a low dose of APAP (15 mg/kg) one to four times per
day for several days and multiple developmental parameters of
offspring health, including AGD and other measurements of
reproductive health, is assessed. That will also require an
evidence-based consensus on what are the most important or
relevant reproductive health parameters to measure.

6. Ototoxicity
Evidence. At least 19 reports of rapidly progressive
sensorineural hearing loss caused by abuse of APAP/opioid
combinations have been published [158-160]. In most cases,
the hearing loss is bilateral, suggesting a systemic cause consistent
with drug exposure. In vitro studies have demonstrated that
long-term (≥24 h) exposure to high concentrations (mM) of
APAP can reduce the number of viable cells in isolated cochlea
(particularly in the outer hair cells) and cause evidence of
apoptotic cell death in an auditory cell line (HEI-OC1) that was
derived from the organ of Corti in the ImmortomouseTM
model [161] and is generally thought to represent cochlear hair
cells [3,8]. Interestingly, co-treatment with hydromorphone
enhanced APAP ototoxicity in these models, though hydromorphone or hydrocodone alone did not cause cell death [8].
NAPQI was shown to have similar effects [13]. Those data
suggested that APAP is the primary cause of hearing loss due
to APAP/opioid abuse. However, no clinical reports of hearing
loss after overdose of APAP alone have been published.
Furthermore, the same group published a more recent study
indicating that APAP does not actually cause cell death in HEIOC1 cells, despite evidence of reduced energy metabolism and
even increased caspase activity [162]. Finally, a recent in vivo
study in mice found no evidence for hearing loss based on
auditory brainstem response (ABR) in a clinically relevant
model of acute APAP overdose [163]. Thus, it seems unlikely
that APAP by itself causes ototoxicity in humans or mice.
Nevertheless, a practical clinical problem clearly exists in
patients treated with opioid/APAP combinations and further
investigation may be warranted.
Proposed mechanisms. Kalinec et al. [13] found that APAP
can cause evidence of oxidative stress in HEI-OC1 cells 12-48
h after initiation of treatment, but that NAPQI does not have
this effect. Furthermore, increased endoplasmic reticulum (ER)
fragmentation was observed in these cells after treatment with
NAPQI but not APAP [13]. Despite the latter, both treatments
altered levels of ER stress markers. Based on these findings, the
authors concluded that APAP and NAPQI exert toxic effects
through different mechanisms in cochlear cells: APAP ototoxicity
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involves oxidative stress and ER stress, while NAPQI causes ER
stress without oxidative stress [13]. The only in vivo study of
APAP ototoxicity to date also revealed that there is oxidative
stress in cochleae after acute APAP overdose [163]; however,
no ototoxicity was observed in that study based on auditory
brainstem thresholds (ABR) [163].
Biological relevance and future studies. While interesting,
the results from cell culture studies thus far are questionable.
First, APAP has a very short half-life in circulation [26].
Thus, it is unlikely to persist at the cochlea for ≥ 24 h, as in
the in vitro experiments described above. Although some
drugs (e.g. aminoglycosides) may become trapped within the
cochlear fluid, this is unlikely to occur with APAP because it
is neutral at physiological pH and readily crosses membranes
[26]. Next, it is not known if HEI-CO1 cells, or cochlear cells in
general, express P450s at concentrations sufficient to convert
APAP to NAPQI. The only study to address that issue
revealed that mice treated with a hepatotoxic dose of APAP
had no evidence of GSH depletion or protein binding in
cochlea [163]. Finally, it is clear that APAP toxicity in vitro
does not necessarily translate to toxicity in vivo. Many cell
lines succumb to APAP toxicity through mechanisms that are
not physiologically relevant. For example, both Hepa 1-6 and
SK-Hep1 liver cells will die after prolonged exposure to mM
concentrations of APAP, despite the fact that these cells do
not form the reactive metabolite of APAP [ 164 , 165 ].
Importantly, the primary mode of cell death in these cells was
found to be apoptosis, which is not a major contributor to
APAP-induced hepatocyte death in vivo [35,50,70, 166 ].
Furthermore, APAP is also toxic to human lymphocytes in
culture [165], but there is little or no evidence that that is true
in vivo. Clearly, it is important to realize that cell culture
studies do not necessarily mimic the in vivo situation.
Overall, it is clear that APAP/opioid combinations are
ototoxic in humans, but there is no strong evidence that
APAP is ototoxic by itself. Future research in this area is
encouraged, and should focus on hearing loss caused by the
combination drugs, and should use only in vivo models with
clear human relevance.

7. Neurodevelopmental and neurobehavioral disorders
Evidence. Several groups have claimed that APAP may be
a cause of autism spectrum disorder (ASD) [7,11,14]. Two major
pieces of evidence led to that hypothesis. First, it was observed
that at least some patients with ASD exhibit defective xenobiotic
sulfation [167]. In fact, when APAP was used as a probe drug
to assess sulfation capacity, the ratio of APAP-sulfate to
APAP-glucuronide was lower in severely autistic subjects
compared to healthy controls [176]. Initially, it was suggested
that this could lead to poor clearance of, and therefore
increased exposure to, certain chemicals present in food or in
the environment that may have neurological effects, but it was
later proposed that APAP itself might be a problem. Schultz
et al. [7] suggested that reduced sulfation may lead to increased
Distributed under creative commons license 4.0
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NAPQI formation with neurotoxic effects. Second, it was found
that diagnoses of ASD began to increase in the 1980s, after the
CDC issued a warning regarding the risk of Reye’s syndrome
and birth defects when treating children or pregnant women
with aspirin, and sales of children’s APAP rose [ 168 ].
However, it is unlikely that reduced sulfation would lead to a
significant increase in NAPQI formation at therapeutic doses of
APAP. Sulfation is a low capacity route of elimination and is
already saturated in healthy subjects at pharmacologic doses of
APAP [ 169 ]. Glucuronidation, on the other hand, is a high
capacity process and does not appear to be saturable [27]. In
fact, the hepatotoxicity of APAP is probably not due to
saturation of Phase II metabolism resulting in greater NAPQI
formation; the percentage of APAP converted to the reactive
metabolite is likely the same regardless of dose. Rather, it is
probably the greater absolute amount of NAPQI that is
produced that initiates liver injury after overdose [27].
Furthermore, the observed correlation between children’s APAP
sales and ASD diagnoses does not prove causation.
Nevertheless, several groups have reported results from
epidemiological studies that seem to show an association between
APAP exposure early in life and development of ASD
[7,11,170]. One of the earliest such studies revealed that parents
of children with autism were more likely to report use of APAP
after receiving the measles-mumps-rubella vaccine [7]. However,
it has been pointed out by others that the parents were solicited
from autism websites and thus were likely to be biased [171]. In
addition, there is the possibility of recall bias in parents of
children with autism who are in search of a cause [171]. More
recent studies have employed more rigorous methods [170].
Unfortunately, even those that have marginalized the risk of
indication bias may still be affected by genetic factors or other
residual bias [172]. Overall, the only human data available to
support the idea that APAP causes ASD are from epidemiological
studies that may be subject to significant bias.
In addition to ASD, it has recently been suggested that
antenatal exposure to APAP may cause hyperactivity or ADD /
ADHD-like behavior in offspring. Liew et al. [7] found an
association between APAP and these disorders in a large
prospective cohort study, and their results are supported by data
from a few other groups [173-176]. However, significant sources of
bias have been pointed out in three of these studies as well
[177], and earlier work by Streissguth et al. [178] provided
conflicting results. Interestingly, one group has even tested the
association between prenatal APAP exposure and ADD/ADHDlike behavior in mice and found no evidence to support it [179],
although it should be noted that there were clear experimental
deficiencies such as a lack of well-validated endpoints for
ADD/ADHD in mice and the fact that a positive control is not
available for comparison. Overall, there is currently no strong
evidence that APAP causes ADD/ADHD.
Although the evidence for neurobehavioral effects of APAP
in humans is poor, multiple studies have demonstrated that
exposure to relatively low doses of APAP during early development
can affect behavioral measures in adult mice [12,180]. While it
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is not possible to make a direct connection between nonspecific behavioral studies in mice and ASD or ADD/ADHD in
humans, these observations are intriguing and may warrant
further investigation. Typically, pregnant women are advised
not to use NSAIDs due to the increased risk of birth defects
and miscarriage that has been reported in a few studies. As a
result, most pregnant women rely on APAP to control fever
and pain. If it can be shown that APAP also poses a
significant risk of congenital abnormalities, then that may
result in removal of the only remaining treatment option for
those patients.
Proposed mechanisms. The proposed mechanisms by
which APAP could cause ASD and ADD/ADHD are similar.
Endocrine disruption, activation of endocannabinoid receptors
during development [181], oxidative stress and inflammation
[182] have all been suggested. However, no studies have been
done to directly test those possibilities. A more straightforward hypothesis is that APAP is directly toxic to neurons.
Posadas et al. [9] tested that by treating rat cortical neurons
with APAP in vitro and by injecting rats with APAP in vivo
and measuring neuron death. They demonstrated that APAP
overdose was moderately toxic to cortical neurons. However,
the purpose of their study was to determine if large doses of
APAP (250-500 mg/kg) are neurotoxic, and it is not known if
typical human doses for therapeutic use (approximately 10-20
mg/kg) have similar effects. Cell death in APAP-treated
cultured neurons has also been reported [9], but again most
cell culture models do not accurately reflect APAP toxicity in
vivo. Finally, it is not clear exactly how neuron death would
lead to ASD and ADD/ADHD.
Biological relevance and future studies. Currently, the
association between APAP and ASD or ADD/ADHD is based on
conflicting results from epidemiological studies. No mechanistic
studies have been performed, and the few mechanisms that
have been proposed have not been directly tested. In fact,
there is strong evidence that ASD, in particular, is driven by
genetics [183], so exposure to APAP or other xenobiotics
may not be important. Males are far more likely to develop
ASD, and siblings of children with ASD are at greater risk [183].
There is also striking evidence for a genetic component of social
behaviors associated with ASD, such as viewing of social
scenes [ 184 ]. Nevertheless, the importance of APAP as a
treatment option during pregnancy, together with the
seriousness of ASD and ADD/ADHD, warrants future
research in this area to enable more definitive conclusions.
Even a simple study could be performed in which pregnant
mice receive 15 mg/kg APAP one to four times per day for
several days and behaviors associated with ASD and
ADD/ADHD are measured in offspring over time.

induction of P450 enzymes in ocular tissue [185,186]. It has
also been suggested that APAP can be cardiotoxic, but this is
based on case reports with no direct evidence [187]. Currently,
there is no compelling evidence for clinically-relevant APAP
toxicity in tissues other than those discussed above.

8. APAP toxicity in other tissues or systems

[2]

APAP toxicity has been reported in other tissues, but the
evidence is limited. For example, APAP is also known to
cause ocular opacity or cataracts in mice, but only after direct

[3]
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9. Conclusions
It has been 50 years since the first reports of APAP-induced
liver injury, and we are only beginning to investigate the
extrahepatic toxicity of the drug in earnest. Renal toxicity after
APAP overdose is known to occur, but the mechanisms have
not been fully elucidated. It is also not known if common comorbidities like alcoholism or obesity affect that outcome. The
pulmonary and neuro- toxicity of APAP are more
controversial. Most data regarding the non-hepatic and nonrenal effects of APAP are from epidemiological studies that do
not prove causation and frequently suffer from bias and/or
conflicting results. Published experimental data provide support
for many of these adverse effects, but too often the data come
from flawed models. However, we believe that some additional
research may be appropriate in at least two areas. The sheer
volume of epidemiological studies that have revealed increased
risk of lung disease after exposure to APAP early in life and
the fact that at least one group has reported a plausible
mechanism based on data from animal models using low doses
of APAP may warrant further investigation of the pulmonary
toxicity of chronic APAP use. Also, the fact that APAP is a
very important drug for pregnant women combined with the
several rodent studies suggesting adverse neurodevelopmental
effects in offspring may warrant further investigation of
neurodevelopmental toxicity to fully evaluate that possibility.
Overall, however, the data for extrahepatic toxicity of APAP
are weak and significant changes in clinical or consumer use
would be not advisable at this time.
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